187 related articles for article (PubMed ID: 18830928)
41. Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S; Lopez-Diaz de Cerio A; Zabalegui N; Soria E; Villanueva H; Panizo C; Rodriguez-Caballero A; Suarez L; Pastor F; Rodriguez-Calvillo M; Orfao A; Bendandi M
Leuk Lymphoma; 2009 Jan; 50(1):47-53. PubMed ID: 19152172
[TBL] [Abstract][Full Text] [Related]
42. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
44. Personalized vaccine for newly diagnosed follicular non-Hodgkin's lymphoma.
Clin Adv Hematol Oncol; 2003 Jan; 1(1):66. PubMed ID: 16227965
[No Abstract] [Full Text] [Related]
45. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic vaccine for lymphoma.
Lee ST; Neelapu SS; Kwak LW
Yonsei Med J; 2007 Feb; 48(1):1-10. PubMed ID: 17326239
[TBL] [Abstract][Full Text] [Related]
47. Plant science. Using tobacco to treat cancer.
Arntzen CJ
Science; 2008 Aug; 321(5892):1052-3. PubMed ID: 18719274
[No Abstract] [Full Text] [Related]
48. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
Armstrong AC; Cheadle EJ; Hawkins RE
BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
[TBL] [Abstract][Full Text] [Related]
49. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma.
Turek MM; Thamm DH; Mitzey A; Kurzman ID; Huelsmeyer MK; Dubielzig RR; Vail DM
Vet Comp Oncol; 2007 Dec; 5(4):219-31. PubMed ID: 19754780
[TBL] [Abstract][Full Text] [Related]
50. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.
Muraro E; Martorelli D; Dolcetti R
Hum Vaccin Immunother; 2013 May; 9(5):1078-83. PubMed ID: 23406835
[TBL] [Abstract][Full Text] [Related]
51. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
52. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
53. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
Longo DL
J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240
[No Abstract] [Full Text] [Related]
54. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF.
Yuan S; Shi C; Han W; Ling R; Li N; Wang T
Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341
[TBL] [Abstract][Full Text] [Related]
55. Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
Assaf C; Sterry W
Curr Opin Mol Ther; 2007 Apr; 9(2):197-203. PubMed ID: 17458175
[TBL] [Abstract][Full Text] [Related]
56. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
57. A year of successful cancer vaccines points to a path forward.
Morse MA; Whelan M
Curr Opin Mol Ther; 2010 Feb; 12(1):11-3. PubMed ID: 20140811
[TBL] [Abstract][Full Text] [Related]
58. Intramuscular immunization with a plasmid DNA vaccine encoding prM-E protein from Japanese encephalitis virus: enhanced immunogenicity by co-administration of GM-CSF gene and genetic fusions of prM-E protein and GM-CSF.
Zhai YZ; Li XM; Zhou Y; Ma L; Feng GH
Intervirology; 2009; 52(3):152-63. PubMed ID: 19521104
[TBL] [Abstract][Full Text] [Related]
59. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
60. Development of vaccine strategies for the treatment of B-cell malignancies.
Kobrin CB; Kwak LW
Cancer Invest; 1997; 15(6):577-87. PubMed ID: 9412664
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
